ATP1A2
Sodium/potassium-transporting ATPase subunit alpha-2
As of the edition of 20 October 2026, ATP1A2 (sodium/potassium-transporting ATPase subunit alpha-2, UniProt P50993) has 5 drugs tested at it and 10 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P50993
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Heart and blood vessels; Cancer; Nutrition and metabolism; Hormones; Skin and connective tissue; Digestive system; Immune system; Infections
- Registered trials of its drugs
- 197
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Digoxin | Marketed | Phase 4 | none listed |
| Istaroxime | Active | Phase 3 | none listed |
| Acetyldigitoxin | Marketed | No phase stated | none listed |
| Deslanoside | Marketed | No phase stated | none listed |
| Digitoxin | Marketed | No phase stated | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 6 |
| Undetermined | 4 |
| Total on the list | 10 |